

Cristina Gervasoni

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4752180/cristina-gervasoni-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

119
papers

2,040
citations

17
h-index

43
g-index

120
ext. papers

2,431
ext. citations

4.8
avg, IF

5.25
L-index

#	Paper	IF	Citations
119	Doravirine/tenofovir disoproxil fumarate/lamivudine-induced alopecia: A case report.. <i>International Journal of STD and AIDS</i> , 2022 , 9564624221096299	1.4	
118	Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. <i>HIV Medicine</i> , 2021 , 22, 372-378	2.7	52
117	Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens. <i>Aids</i> , 2021 , 35, 2551-2553	3.5	0
116	Differences in tenofovir trough concentrations between branded and generic formulations in people taking PrEP. <i>Aids</i> , 2021 , 35, 522-524	3.5	
115	Drug-Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients. <i>Drugs and Aging</i> , 2021 , 38, 341-346	4.7	2
114	Comment on "Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6". <i>Clinical Pharmacokinetics</i> , 2021 , 60, 829-831	6.2	1
113	ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment. <i>Pharmacogenomics Journal</i> , 2021 , 21, 586-593	3.5	2
112	Ritonavir/Cobicistat-Induced Cushing Syndrome in HIV Patients Treated With Non-Oral Corticosteroids: A Call for Action?. <i>American Journal of the Medical Sciences</i> , 2021 , 361, 137-139	2.2	0
111	Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 103-109	6.2	6
110	Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study. <i>Journal of Medical Virology</i> , 2021 , 93, 1421-1427	19.7	17
109	Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts. <i>European Journal of Clinical Pharmacology</i> , 2021 , 77, 791-792	2.8	1
108	Supra-therapeutic Linezolid Trough Concentrations in Elderly Patients: A Call for Action?. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 603-609	6.2	1
107	Liver Injury After Dietary Supplements in Patients Living With HIV: A Call to Action. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	
106	When the absence of an interaction can become clinically relevant. <i>Aids</i> , 2021 , 35, 1327-1328	3.5	0
105	Preventing COVID-19 in assisted living facilities: An impossible task pending vaccination roll out. <i>Preventive Medicine Reports</i> , 2021 , 23, 101471	2.6	2
104	Trials and tribulations of coronavirus disease-2019 research: with a few bright lights in the fog. <i>Journal of Cardiovascular Medicine</i> , 2020 , 21, 841-844	1.9	3
103	Does lopinavir really inhibit SARS-CoV-2?. <i>Pharmacological Research</i> , 2020 , 158, 104898	10.2	26

102	Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2704-2706	5.1	26
101	Clinical Features and Outcomes of Patients With Human Immunodeficiency Virus With COVID-19. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2276-2278	11.6	114
100	Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings. <i>Drugs in R and D</i> , 2020 , 20, 155-160	3.4	1
99	Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study. <i>Clinical Infectious Diseases</i> , 2020 , 71, 889-890	11.6	754
98	Darunavir does not prevent SARS-CoV-2 infection in HIV patients. <i>Pharmacological Research</i> , 2020 , 157, 104826	10.2	40
97	Use of Direct Oral Anticoagulants in People Living with HIV: A Single-Center Experience. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 999-1001	5.3	1
96	Liver Injury After Occasional Energy Drink Use in a Patient Living With HIV and Diabetes. <i>Annals of Pharmacotherapy</i> , 2020 , 54, 292-293	2.9	2
95	Effects of ursodeoxycholic acid on rilpivirine plasma trough concentrations: a case report. <i>European Journal of Clinical Pharmacology</i> , 2020 , 76, 605-606	2.8	
94	Impact of Therapeutic Drug Monitoring of Antiretroviral Drugs in Routine Clinical Management of People Living With HIV: A Narrative Review. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 64-74	3.2	6
93	Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 330-334	3.2	3
92	The prescribing cascade 3.0: a case for recreational drugs in HIV. <i>Aids</i> , 2020 , 34, 1253-1255	3.5	1
91	COVID-19 trials in Italy: A call for simplicity, top standards and global pooling. <i>International Journal of Cardiology</i> , 2020 , 318, 160-164	3.2	2
90	Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. <i>Drugs and Aging</i> , 2020 , 37, 925-933	4.7	12
89	Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report. <i>International Journal of STD and AIDS</i> , 2020 , 31, 1008-1010	1.4	3
88	Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 ,	5.9	2
87	A Comparison of Tenofovir Predose Concentrations in Generic Pre-exposure Prophylaxis Formulations: A Short Communication. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 643-647	3.2	2
86	Association of HIV Infection with Epilepsy and Other Comorbid Conditions. <i>AIDS and Behavior</i> , 2020 , 24, 1051-1055	4.3	0
85	Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice. <i>World Journal of Biological Psychiatry</i> , 2020 , 21, 651-657	3.8	6

84	The management of anti-infective agents in intensive care units: the potential role of a Gastro pharmacology. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 355-366	3.8	2
83	Management of Polypharmacy and Drug-Drug Interactions in HIV Patients: A 2-year Experience of a Multidisciplinary Outpatient Clinic. <i>AIDS Reviews</i> , 2019 , 21, 40-49	1.5	8
82	Drug-induced liver steatosis in patients with HIV infection. <i>Pharmacological Research</i> , 2019 , 145, 104267	10.2	2
81	Effects of guggulsterones-containing thermogenic complex on elvitegravir plasma concentrations: a case report. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 1177-1178	2.8	2
80	Assessment of Antiepileptic Drug Concentrations in HIV-Infected versus HIV-Negative Patients: A Retrospective Analysis. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 1345-1350	6.2	1
79	Different effects of glucocorticoids on darunavir plasma concentrations. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 733-735	2.8	2
78	No effects of Hypericum-containing complex on dolutegravir plasma trough concentrations: a case report. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 1467-1468	2.8	2
77	Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 59-65	3.2	4
76	Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019 , 44, 319-327	2.7	19
75	Genomic Characterization of an ST1153 PVL-producing Methicillin Resistant Staphylococcus aureus Clinical Isolate in Italy. <i>New Microbiologica</i> , 2019 , 42, 129-131	1.1	
74	Dolutegravir and metformin: a clinically relevant or just a pharmacokinetic interaction?. <i>Aids</i> , 2018 , 32, 532-533	3.5	7
73	Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 77, 86-92	3.1	19
72	Remitting infections due to community-acquired Panton-Valentine leukocidin-producing Staphylococcus aureus in the Milan area. <i>Journal of Infection and Public Health</i> , 2018 , 11, 255-259	7.4	3
71	How relevant are the drug-drug interactions between antiretroviral boosted-based regimens and calcium channel blockers in real life?. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2271-2273	5.1	5
70	Loss of Control of HIV Viremia With OTC Weight-Loss Drugs: A Call for Caution?. <i>Obesity</i> , 2018 , 26, 1251-1252	8.252	5
69	Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. <i>Antiviral Therapy</i> , 2018 , 23, 249-257	1.6	6
68	The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration. <i>Antiviral Therapy</i> , 2018 , 23, 467-469	1.6	2
67	Psychoactive drugs and HIV: are we sure to treat our patients adequately?. <i>Aids</i> , 2018 , 32, 127-128	3.5	

66	Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 78, 193-201	3.1	15
65	Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017 , 42, 559-572	2.7	3
64	The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir. <i>European Journal of Clinical Pharmacology</i> , 2017 , 73, 789-790	2.8	2
63	Intolerance of dolutegravir-containing combination antiretroviral therapy: not just a pharmacokinetic drug interaction. <i>Aids</i> , 2017 , 31, 867-868	3.5	10
62	How Relevant is the Interaction Between Dolutegravir and Metformin in Real Life?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 75, e24-e26	3.1	15
61	Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors. <i>Drug Metabolism and Personalized Therapy</i> , 2017 , 32, 115-117	2	
60	Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1842-1844	5.1	16
59	Elvitegravir/cobicistat-associated toxic optical neuropathy in an HIV-infected patient: a call for caution?. <i>Antiviral Therapy</i> , 2017 , 22, 453-455	1.6	4
58	Pregnancy-related changes of antiretroviral pharmacokinetics: an argument for therapeutic drug monitoring. <i>Antiviral Therapy</i> , 2017 , 22, 361-363	1.6	2
57	Is it time to revise linezolid dose in elderly patients?. <i>European Journal of Clinical Pharmacology</i> , 2017 , 73, 1335-1336	2.8	5
56	Renal function in HIV/HBV co-infected and HBV mono-infected patients on a long-term treatment with tenofovir in real life setting. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017 , 44, 191-196	3.6	7
55	Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?. <i>Antiviral Therapy</i> , 2017 , 22, 353-356	1.6	10
54	Therapeutic drug management of linezolid: a missed opportunity for clinicians?. <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 728-731	14.3	25
53	Determinants of bone diseases in tenofovir-treated HIV patients. <i>Aids</i> , 2016 , 30, 1686-7	3.5	1
52	Abacavir-induced liver toxicity. <i>Brazilian Journal of Infectious Diseases</i> , 2016 , 20, 502-4	2.8	8
51	Reduced raltegravir clearance in HIV-infected liver transplant recipients: an unexpected interaction with immunosuppressive therapy?. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1341-5	5.1	4
50	Relapse of Kaposi's Sarcoma and HHV-8 viremia in an HIV-infected patient switching from protease inhibitor to integrase inhibitor-based antiretroviral therapy. <i>Journal of Clinical Virology</i> , 2016 , 74, 75-7	14.5	10
49	Orlistat: weight lost at cost of HIV rebound. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1739-41	5.1	7

48	Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 365-7	2.8	3
47	Comparison of the In Vivo Pharmacokinetics and In Vitro Dissolution of Branded Versus Generic Efavirenz Formulation in HIV-Infected Patients. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 420-2	3.2	2
46	Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 285-7	3.2	1
45	Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?. <i>European Respiratory Journal</i> , 2016 , 47, 1287-8	13.6	3
44	Darunavir-based Antiretroviral Therapy may Affect the Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in HCV/HIV-1 Coinfected Patients. <i>Clinical Infectious Diseases</i> , 2016 , 63, 285-6	11.6	7
43	When food can make the difference: The case of elvitegravir-based co-formulation. <i>International Journal of Pharmaceutics</i> , 2016 , 512, 301-304	6.5	7
42	Simeprevir-induced severe withdrawal syndrome in an HIV/HCV coinfecting patient on long-term maintenance methadone therapy. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 1027-8	2.8	7
41	Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers: a randomized, open-label, 2-period, single-dose, crossover phase 1 study. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 119-25	3.2	2
40	Linezolid-related haematological toxicity in a peritoneal dialysis patient: the role of therapeutic drug monitoring. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 383-5	2.8	3
39	Prolonged inductive effect of rifampicin on linezolid exposure. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 643-4	2.8	8
38	Effect of hepatitis B and C clearance on atazanavir exposure. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 1409-11	2.8	0
37	Is it time to revise linezolid doses in peritoneal dialysis patients? A case series. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2918-20	5.1	10
36	Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients. <i>Antiviral Therapy</i> , 2015 , 20, 449-51	1.6	3
35	Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 545-9	14.3	4
34	Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?. <i>PLoS ONE</i> , 2015 , 10, e0123670	3.7	22
33	Telaprevir therapy, renal impairment, and their effects on the pharmacokinetics of tenofovir in HIV/hepatitis C virus coinfecting patients. <i>Aids</i> , 2014 , 28, 285-7	3.5	5
32	Recurrence of another hepatitis B virus escape mutant comes back in a patient infected with HIV and low CD4+ count. <i>Journal of Medical Virology</i> , 2014 , 86, 97-101	19.7	6
31	Levofloxacin-induced seizures in a patient without predisposing risk factors: the impact of pharmacogenetics. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 1611-3	2.8	11

30	ACE inhibitors and ribavirin-associated cough: a common undefined predisposing factor?. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 743-5	2.8	3
29	Systemic lupus erythematosus and HIV infection: a whimsical relationship. Reports of two cases and review of the literature. <i>Clinical Rheumatology</i> , 2013 , 32, 1399-405	3.9	30
28	Is chewed raltegravir an option to care for HIV-infected patients with active tuberculosis?. <i>Clinical Infectious Diseases</i> , 2013 , 57, 480-1	11.6	3
27	Seizures in patients with chronic hepatitis C treated with NS3/4A protease inhibitors: does pharmacological interaction play a role?. <i>Pharmacology</i> , 2013 , 92, 235-7	2.3	3
26	Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1206-7	5.1	5
25	Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events. <i>PLoS ONE</i> , 2013 , 8, e80242	3.7	30
24	Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 440-5	2.9	12
23	Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients. <i>Pharmacological Research</i> , 2012 , 65, 198-203	10.2	17
22	HIV education and counselling using Facebook: a possible new approach. <i>Journal of Telemedicine and Telecare</i> , 2012 , 18, 239-40	6.8	7
21	Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 6132-6 ⁹	5.9	27
20	Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 460-4	5.1	48
19	Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 2236-42	5.1	16
18	Pharmacokinetic concerns related to the AIDS Clinical Trial Group (ACTG) A5262 trial. <i>Aids</i> , 2012 , 26, 398-400; author reply 397-8	3.5	4
17	Reply to Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients <i>Aids</i> , 2011 , 25, 1012-3; author reply 1011-2	3.5	2
16	Tubercular gluteus abscesses: a return to the early 20th century or a consequence of new, unprecedented behaviors?. <i>Clinical Infectious Diseases</i> , 2011 , 52, 1082-3	11.6	4
15	Enfuvirtide administration in HIV-positive transgender patient with soft tissue augmentation: US evaluation. <i>New Microbiologica</i> , 2010 , 33, 263-5	1.1	
14	Proven intra and interobserver reliability in the echographic assessments of body fat changes related to HIV associated Adipose Redistribution Syndrome (HARS). <i>Current HIV Research</i> , 2008 , 6, 276-8 ^{1.3}		2
13	Comparability of echographic and tomographic assessments of body fat changes related to the HIV associated adipose redistribution syndrome (HARS) in antiretroviral treated patients. <i>Ultrasound in Medicine and Biology</i> , 2008 , 34, 1043-8	3.5	5

12	Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation. <i>AIDS Patient Care and STDs</i> , 2007 , 21, 1-3	5.8	16
11	Long-term efficacy of the surgical treatment of buffalo hump in patients continuing antiretroviral therapy. <i>Aids</i> , 2004 , 18, 574-6	3.5	17
10	Pneumocystis carinii pneumonia after the discontinuation of long-term antiretroviral therapy in an HIV-1-infected pregnant woman. <i>Aids</i> , 2003 , 17, 940-1	3.5	
9	Correlates of Risk of Adipose Tissue Alterations and Their Modifications over Time in HIV-1-Infected Women Treated with Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2003 , 8, 347-354	1.6	7
8	Maintenance of breast size reduction after mastoplasty and switch to a protease inhibitor-sparing regimen in an HIV-positive woman with highly active antiretroviral therapy-associated massive breast enlargement. <i>AIDS Patient Care and STDs</i> , 2002 , 16, 307-11	5.8	11
7	Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2002 , 35, 1534-40	11.6	64
6	Fat redistribution in HIV-infected patients. A new hormonal-immune disorder?. <i>Annals of the New York Academy of Sciences</i> , 2000 , 917, 951-5	6.5	9
5	Immunoendocrinologic abnormalities in human immunodeficiency virus infection. <i>Annals of the New York Academy of Sciences</i> , 2000 , 917, 956-61	6.5	29
4	Body habitus alterations in HIV-infected women treated with combined antiretroviral therapy. <i>AIDS Patient Care and STDs</i> , 2000 , 14, 595-601	5.8	8
3	Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. <i>Aids</i> , 1999 , 13, 465-71	3.5	234
2	Fatal septic shock due to <i>Gemella morbillorum</i> in two HIV-positive patients. <i>Clinical Microbiology and Infection</i> , 1996 , 2, 65-66	9.5	1
1	Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-COV-2 infection: a retrospective cohort study		1